English | 繁體

Search in the results

UM

Browse/Search Results:  1-6 of 6 Help

Selected(0)Clear Items/Page:    Sort:
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov Journal article
Yang, Jing, Kang, Heming, Lyu, Liyang, Xiong, Wei, Hu, Yuanjia. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov[J]. Discover Oncology, 2023, 14(1), 151.
Authors:  Yang, Jing;  Kang, Heming;  Lyu, Liyang;  Xiong, Wei;  Hu, Yuanjia
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date：2023/09/21
Bispecific Antibodies  Combination Therapy  Immuno-oncology Therapy  Kinase Inhibitors  Pd-1/pd-l1 Inhibitors  Targeted Therapy  
Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer Journal article
Xie Ying, Feng SenLing, He Fang, Yan PeiYu, Yao XiaoJun, Fan XingXing, Leung Elaine Lai Han, Zhou Hua. Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer[J]. PHARMACOLOGICAL RESEARCH, 2022, 186, 106514.
Authors:  Xie Ying;  Feng SenLing;  He Fang;  Yan PeiYu;  Yao XiaoJun; et al.
Favorite | TC[WOS]:15 TC[Scopus]:14  IF:9.1/9.0 | Submit date：2023/01/30
Drug Resistance  Chemotherapy  Egfr Tyrosine Kinase Inhibitors  Nrf2  Tangeretin  
Targeting cd82/kai1 for precision therapeutics in surmounting metastatic potential in breast cancer Review article
2021
Authors:  Viera, Maximillian;  Yip, George Wai Cheong;  Shen, Han Ming;  Baeg, Gyeong Hun;  Bay, Boon Huat
Favorite | TC[WOS]:2 TC[Scopus]:4  IF:4.5/4.9 | Submit date：2021/11/30
Metastasis Suppressor  Tetraspanins  Tyrosine Kinase Inhibitors  Etoposide  Cd82 Mimics  Epigenetic Drugs  
Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics Journal article
Zhang W., Hu X., Chakravarty H., Yang Z., Tam K.Y.. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics[J]. ACS Combinatorial Science, 2018, 20(11), 660-671.
Authors:  Zhang W.;  Hu X.;  Chakravarty H.;  Yang Z.;  Tam K.Y.
Favorite | TC[WOS]:12 TC[Scopus]:12 | Submit date：2018/12/18
Cancer  High-throughput Screening  Pyruvate Dehydrogenase Kinase 1  Small Molecule Inhibitors  Warburg Effect  
Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics Journal article
Zhang, W., Hu, X., Chakravarty, H., Yang, Z., Tam, K. Y.. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics[J]. ACS Combinatoral Science, 2018, 660-671.
Authors:  Zhang, W.;  Hu, X.;  Chakravarty, H.;  Yang, Z.;  Tam, K. Y.
Favorite | TC[WOS]:12 TC[Scopus]:12  IF:3.903/3.637 | Submit date：2022/07/28
Cancer  Warburg Effect  High-throughput Screening  Pyruvate Dehydrogenase Kinase 1  Small Molecule Inhibitors  
Development of dichloroacetamide pyrimidine derivatives as pyruvate dehydrogenases kinase inhibitor to reduce cancer cell growth: synthesis and biological evaluation Journal article
Zhang, S., Zhang, W., Xiao, Q., Yang, Z., Hu, X., Wei, Z., Tam, K. Y.. Development of dichloroacetamide pyrimidine derivatives as pyruvate dehydrogenases kinase inhibitor to reduce cancer cell growth: synthesis and biological evaluation[J]. RSC Advances, 2016, 78762-78767.
Authors:  Zhang, S.;  Zhang, W.;  Xiao, Q.;  Yang, Z.;  Hu, X.; et al.
Favorite | TC[WOS]:4 TC[Scopus]:5  IF:3.9/3.9 | Submit date：2022/07/28
Pyruvate Dehydrogenases Kinase Inhibitors  Anticancer Treatment